{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:45:40Z","timestamp":1772084740879,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272312"],"award-info":[{"award-number":["82272312"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study was the first to examine the association of baseline clinical factors with the rate of HBsAg clearance in a large retrospective cohort of Chinese patients with HIV\/HBV coinfection treated with combination antiretroviral therapy (ART).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our retrospective cohort included 431 patients with HIV\/HBV coinfection treated with TDF-containing ART. The median follow-up was 6.26 years. Logistic regression was used to investigate the association of baseline variables with HBsAg clearance, and Cox regression was used to investigate the association of baseline variables with time to HBsAg clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The clearance rate of HBsAg in our study was 0.072 (95% CI 0.049~0.101). In the multivariate logistic regression, advanced age (OR=1.1, P=0.007), high CD4 cell count (OR=2.06, P=0.05), and HBeAg positivity (OR=8.00, P=0.009) were significantly associated with the rate of HBsAg clearance. The AUC of the model integrating the above three predictors was 0.811. Similar results were found in the multivariate Cox regression (HR = 1.09, P = 0.038 for age, HR = 1.05, P = 0.012 for CD4 count and HR = 7.00, P = 0.007 for HBeAg).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Long-term TDF-containing ART can lead to HBsAg clearance of 7.2% in Chinese patients with HIV\/HBV coinfection. Advanced age, high CD4 cell count, and positive HBeAg at baseline could be regarded as potential predictors and biological markers for HBsAg clearance in patients with HIV\/HBV coinfection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2023.1130485","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T05:47:09Z","timestamp":1675835229000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence and predictors of HBV functional cure in patients with HIV\/HBV coinfection: A retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Qingrong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000002386","article-title":"Long-term TDF-inclusive ART and progressive rates of HBsAg loss in HIV-HBV coinfection\u2013lessons for functional HBV cure","volume":"84","author":"Audsley","year":"2020","journal-title":"JAIDS J. Acquired Immune Deficiency Syndromes"},{"key":"B2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.3851\/IMP1645","article-title":"\u201cEfficacy of tenofovir disoproxil fumarate\/ emtricitabine compared with emtricitabine alone in antiretroviral-naive HIV\u2013HBV coinfection in thailand\u201d","volume":"15","author":"Avihingsanon","year":"2010","journal-title":"Antiviral Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"11135","DOI":"10.1073\/pnas.0403925101","article-title":"Genomic DNA double-strand breaks are targets for hepadnaviral DNA integration","volume":"101","author":"Bill","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"214265","DOI":"10.7448\/IAS.20.1.21426","article-title":"\u201cLiver fibrosis regression and progression during controlled hepatitis b virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: A prospective cohort study","volume":"20","author":"Boyd","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"B5","doi-asserted-by":"publisher","first-page":"13415","DOI":"10.3390\/v13071341","article-title":"Functional cure of hepatitis b virus infection in individuals with HIV-coinfection: A literature review","volume":"13","author":"Boyd","year":"2021","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1097\/QAD.0000000000000795","article-title":"Rates and determinants of hepatitis b \u2018e\u2019 antigen and hepatitis b surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis b virus","volume":"29","author":"Boyd","year":"2015","journal-title":"AIDS"},{"key":"B7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.13156","article-title":"Hepatitis b surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis b virus coinfected patients from Sub-Saharan Africa: Seroclearance during treatment","volume":"31","author":"Boyd","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1111\/liv.14684","article-title":"Obstacles to HBV functional cure: Late presentation in HIV and its impact on HBV seroconversion in HIV\/HBV coinfection","volume":"40","author":"Bremen","year":"2020","journal-title":"Liver Int."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.713981","article-title":"HBV\/HIV coinfection: Impact on the development and clinical treatment of liver diseases","volume":"8","author":"Cheng","year":"2021","journal-title":"Front. Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"8375","DOI":"10.2307\/2531595","article-title":"\u201cComparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach\u201d","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0215464","article-title":"Higher rates of HBsAg clearance with tenofovir-containing therapy in HBV\/HIV Co-infection","volume":"14","author":"Gantner","year":"2019","journal-title":"PloS One"},{"key":"B12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/QAI.0b013e3182a60f7d","article-title":"HIV\u2013HBV coinfection in southern Africa and the effect of lamivudine- versus tenofovir-containing CART on HBV outcomes","volume":"64","author":"Hamers","year":"2013","journal-title":"J. Acquir. Immune De\ufb01c Syndr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/QAD.0000000000003193","article-title":"Hepatitis b surface antigen and hepatitis b RNA changes in HIV\/Hepatitis b virus Co-infected participants receiving hepatitis b virus-active antiretroviral therapy","volume":"36","author":"Hawkins","year":"2022","journal-title":"AIDS"},{"key":"B14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12072-019-09953-4","article-title":"Long-term virological and serologic responses of chronic hepatitis b virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis b coinfection","volume":"13","author":"Huang","year":"2019","journal-title":"Hepatol. Int."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab116","article-title":"Incidence and predictors of hepatitis b surface antigen clearance in HIV patients: A retrospective multisite study","volume":"8","author":"Jain","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01023","article-title":"Immunological efficacy of tenofovir disproxil fumarate-containing regimens in patients with HIV-HBV coinfection: A systematic review and meta-analysis","volume":"10","author":"Jiang","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/hep.31839","article-title":"Risk of HCC with hepatitis b viremia among HIV\/HBV-coinfected persons in north America","volume":"74","author":"Kim","year":"2021","journal-title":"Hepatology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/cid\/ciz1170","article-title":"Global burden of hepatitis b infection in people living with human immunodeficiency virus: A systematic review and meta-analysis","volume":"71","author":"Leumi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/QAI.0000000000000927","article-title":"Lamivudine monotherapy-based CART is efficacious for HBV treatment in HIV\/HBV coinfection when baseline HBV DNA <20,000 IU\/ML","volume":"72","author":"Li","year":"2016","journal-title":"JAIDS J. Acquired Immune Deficiency Syndromes"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061297","article-title":"Quantitative HBsAg and HBeAg predict hepatitis b seroconversion after initiation of HAART in HIV-HBV coinfected individuals","volume":"8","author":"Matthews","year":"2013","journal-title":"PloS One"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1093\/cid\/cit002","article-title":"Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis b virus","volume":"56","author":"Matthews","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1097\/QAD.0b013e328352224d","article-title":"Kinetics of hepatitis b surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV\u2013hepatitis b virus-infected patients","volume":"26","author":"Maylin","year":"2012","journal-title":"AIDS"},{"key":"B23","article-title":"Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Disease Society of America","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/hep.31823","article-title":"A prospective study evaluating changes in histology, clinical and virologic outcomes in HBV-HIV Co-infected adults in north America","volume":"74","author":"Sterling","year":"2021","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ajg.2009.669","article-title":"Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age\u201d","volume":"105","author":"Tai","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.893512","article-title":"Immune mechanisms underlying hepatitis b surface antigen seroclearance in chronic hepatitis b patients with viral coinfection","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"180355","DOI":"10.1038\/nrdp.2018.35","article-title":"Hepatitis b virus infection\u201d","volume":"4","author":"Yuen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"B28","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/infdis\/jis439","article-title":"Hepatitis b surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV","volume":"206","author":"Zoutendijk","year":"2012","journal-title":"J. Infect. Dis."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1130485\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T05:47:13Z","timestamp":1675835233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1130485\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":28,"alternative-id":["10.3389\/fcimb.2023.1130485"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1130485","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]},"article-number":"1130485"}}